We are live on ! Find out more
VRAX icon

Virax Biolabs

4 hedge funds and large institutions have $72.4K invested in Virax Biolabs in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 2 → 4 (+2)

0.85% more ownership

Funds ownership: 3.31% → 4.16% (+0.85%)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

VRAX Hedge Fund Activity: Q3 2026 in Review

4 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2026, worth a combined $72.4K — down 6.6% from $77.6K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VRAX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, adding an estimated $19.5K.

  • 4 institutional investors held Virax Biolabs (VRAX) as of Q3 2026, up from 2 in Q2 2026.
  • Funds reported $72.4K of Virax Biolabs stock for Q3 2026, down 6.6% quarter-over-quarter.
  • 2 funds opened new Virax Biolabs positions in Q3 2026 and 0 closed out, a net change of +2 holders.
  • The largest Virax Biolabs buyer in Q3 2026 was Jane Street, an estimated $19.5K added.

Based on aggregated 13F filings for Q3 2026.